We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breakthrough Diagnostic Technology Enables Quantitative Five-Minute Tests

By LabMedica International staff writers
Posted on 09 Nov 2022

Fast and accurate diagnostic results have become familiar. More...

But many medical decisions rely on a quantitative diagnostic result. The doctor needs a number, not just a positive or negative. Now, a breakthrough diagnostic technology enables quantitative five-minute tests that deliver easy, immediate and accurate results to expedite medical treatment.

ProciseDx Inc. (San Diego, CA, USA) has received FDA clearance of its ProciseDx instrument and C reactive Protein (CRP) test. Procise CRP gives quantitative determination of CRP levels in patient serum in less than five minutes. The company expects FDA clearances of additional tests in 2023. ProciseDx has a menu of five-minute gastroenterology and Therapeutic Drug Monitoring (TDM) tests available in Europe.

ProciseDx has obtained CE Marks and launched four gastroenterology (GI) tests in Europe. Already 30 ProciseDx instruments are installed and supporting patient care, with a further 50 sites working towards implementation. For the US market, ProciseDx has submitted De Novo applications to the FDA for two TDM tests. Procise IFX measures infliximab (Remicade and biosimilars) and Procise ADL measures adalimumab (Humira and biosimilars). ProciseDx expects to commercialize its GI and TDM menu in the US in 2023, launching with Procise IFX, Procise ADL and Procise CRP.

"Accurate quantitative diagnostic results have typically required big lab instruments and taken several hours or days," said Larry Mimms, President & Chief Scientific Officer. "The ProciseDx platform can change that, with a simple workflow producing a reliable quantitative measurement in five minutes or less."

"Remicade and Humira are hugely important drugs for patients with IBD (Inflammatory Bowel Disease) and ProciseDx monitoring of these drugs is improving care in Europe," said Peter Westlake, ProciseDx CEO. "ProciseDx technology is a real step forward, because it can deliver reliable quantitative results from a drop of blood in five minutes or less. We're preparing to bring these additional ProciseDx five-minute tests to doctors and patients in the US."

Related Links:
ProciseDx Inc.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Manual Pipetting Aid
Pipette Controllers macro
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.